Skip to content
PubMed This is a summary of 14 peer-reviewed journal articles Updated
Genetics

Standard of Care Treatment & Management

At a Glance

Citrullinemia Type I (CTLN1) is managed through a low-protein diet, nitrogen-scavenging medications, and arginine supplements to prevent dangerous ammonia buildup. Severe cases may require emergency dialysis or a liver transplant, which provides working enzymes and allows for a normal diet.

Managing Citrullinemia Type I (CTLN1) requires a dual approach: a strict daily routine to maintain balance and a rapid-response plan for emergencies. The goal of treatment is to keep ammonia levels low to protect the brain and support normal growth [1][2].

Acute Management: The Emergency Response

A metabolic crisis is a life-threatening emergency. If ammonia levels rise rapidly, the medical team must act quickly to stop the production of new ammonia and remove what is already in the blood [1][3].

  • Stop All Dietary Protein: The fundamental first step in any metabolic emergency is to immediately halt all dietary protein intake (usually for 24-48 hours) to stop adding nitrogen to the system [4].
  • Stopping Catabolism: While stopping protein, doctors provide high amounts of intravenous (IV) glucose (sugar) and sometimes lipids (fats) to give the body immediate energy. This stops the body from breaking down its own muscle tissue [5].
  • IV Nitrogen Scavengers: Medications like sodium benzoate and sodium phenylacetate are given through an IV. These drugs act as “detour routes,” allowing the body to bypass the broken urea cycle and excrete nitrogen through urine [1].
  • Dialysis (CRRT): If medications aren’t lowering ammonia fast enough, doctors may use continuous renal replacement therapy (CRRT) or hemodialysis. These machines filter the blood directly to remove ammonia, which is critical for preventing brain swelling [6][7].

Chronic Management: The Daily Routine

Once stabilized, the focus shifts to preventing future crises through a combination of diet and medication [2].

Dietary Protein Restriction & Infant Feeding

Since nitrogen comes from protein, individuals with CTLN1 must eat a low-protein diet [4]. This is a delicate balance; the body still needs some protein to grow.

  • Can I breastfeed? Yes, in many cases, but it must be strictly managed. Parents often do “combination feeding”—measuring out a very specific amount of breast milk (or standard infant formula) to provide just enough natural protein for growth, and then filling the rest of the baby’s calorie needs with a medical formula that contains essential amino acids but zero whole protein [4]. Your metabolic dietitian will give you an exact “recipe” to follow.

Nitrogen Scavengers and Supplements

These medications are taken daily to continuously clear waste nitrogen from the body [8].

  • Sodium Phenylbutyrate: A powder or tablet that can have a very salty, bitter taste [9].
  • Glycerol Phenylbutyrate (Ravicti): A newer, nearly tasteless liquid formulation that is often easier for children and adults to tolerate [9][10].
  • Arginine Supplementation: In CTLN1, the body cannot make its own arginine, a vital amino acid. Daily supplements are required to keep the cycle moving [2][11].

Liver Transplantation: A “Functional Cure”

For many children with the severe neonatal form of CTLN1, a liver transplant is considered the best long-term option [12].

The idea of an infant needing a liver transplant is deeply frightening. However, it is important context that pediatric liver transplantation is a well-established, highly successful procedure that is routinely used for severe metabolic disorders [12].

  • The Benefit: Replacing the liver provides the body with a “new factory” of working enzymes. After a successful transplant, patients can typically eat a normal diet and stop taking nitrogen-scavenging medications, severely reducing the risk of a metabolic crisis [12][13].
  • The Trade-off: A transplant requires taking immunosuppressant (anti-rejection) medications for the rest of their life [12]. Also, a transplant cannot reverse existing brain damage caused by previous crises, which is why specialists often recommend early evaluation [12].

Monitoring for Success

Long-term success is measured through regular blood tests [2].

  • Ammonia Monitoring: Keeping levels well below the danger zone (<80100 μmol/L<80-100\text{ }\mu\text{mol/L}) [14].
  • Amino Acid Profiles: Checking that arginine, glutamine, and citrulline levels stay within target ranges [2][4].

Return to Home Page

Common questions in this guide

How is a metabolic crisis managed in Citrullinemia type I?
A metabolic crisis is a medical emergency requiring immediate action to lower ammonia levels. Doctors will stop all dietary protein, provide IV glucose for energy, and give IV nitrogen scavenger medications or use dialysis to filter ammonia from the blood.
Can a mother breastfeed an infant with Citrullinemia type I?
Yes, in many cases, but it must be strictly managed with combination feeding. Parents provide a specific amount of breast milk for natural protein and fill the remaining calorie needs with a specialized medical formula that contains zero whole protein.
What daily medications are used to manage CTLN1?
Patients take daily nitrogen-scavenging medications, such as sodium phenylbutyrate or glycerol phenylbutyrate (Ravicti), to clear waste nitrogen. They also take daily arginine supplements, as their bodies cannot produce this essential amino acid on their own.
Why is a liver transplant considered for Citrullinemia type I?
A liver transplant provides the body with working enzymes, significantly reducing the risk of a metabolic crisis. After a successful transplant, patients can typically eat a normal diet and stop taking nitrogen-scavenging medications, though they will need lifelong anti-rejection drugs.
How do doctors monitor the long-term success of CTLN1 treatments?
Long-term success is monitored through regular blood tests. Doctors will track ammonia levels to ensure they stay below the danger zone and check amino acid profiles to make sure arginine, glutamine, and citrulline remain within their target ranges.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is my child's specific daily protein allowance, and how should it be adjusted as they grow?
  2. 2.Is my child a candidate for glycerol phenylbutyrate (Ravicti), and how does it compare to sodium phenylbutyrate in terms of taste and adherence?
  3. 3.At what point do you recommend we start a formal evaluation for a liver transplant?
  4. 4.Can we review the 'Emergency Letter' to ensure it includes the correct dosages for IV nitrogen scavengers and glucose infusion?
  5. 5.How often should we be testing plasma amino acids to ensure my child is getting enough arginine and not becoming protein-malnourished?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (14)
  1. 1

    A Case of Atypical Adult Presentation of Urea Cycle Disorder.

    Wang B, Jha P

    WMJ : official publication of the State Medical Society of Wisconsin 2019; (118(2)):98-100.

    PMID: 31532938
  2. 2

    Treatment and management for children with urea cycle disorder in chronic stage.

    Huang X

    Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences 2023; (52(6)):744-750 doi:10.3724/zdxbyxb-2023-0378.

    PMID: 37807629
  3. 3

    Late-Onset Ornithine Transcarbamylase Deficiency Complicated with Extremely High Serum Ammonia Level: Prompt Induction of Hemodialysis as the Key to Successful Treatment.

    Yamamoto S, Yamashita S, Kakiuchi T, et al.

    The American journal of case reports 2022; (23()):e937658 doi:10.12659/AJCR.937658.

    PMID: 36377209
  4. 4

    Urea Cycle Related Amino Acids Measured in Dried Bloodspots Enable Long-Term In Vivo Monitoring and Therapeutic Adjustment.

    Baruteau J, Khalil Y, Grunewald S, et al.

    Metabolites 2019; (9(11)) doi:10.3390/metabo9110275.

    PMID: 31718089
  5. 5

    Acute pediatric hyperammonemia: current diagnosis and management strategies.

    Savy N, Brossier D, Brunel-Guitton C, et al.

    Hepatic medicine : evidence and research 2018; (10()):105-115 doi:10.2147/HMER.S140711.

    PMID: 30254497
  6. 6

    Fatal Encephalopathy Caused by a Urea Cycle Disorder.

    Park SH, Lee JH, Choi SJ, et al.

    Journal of clinical neurology (Seoul, Korea) 2021; (17(2)):325-327 doi:10.3988/jcn.2021.17.2.325.

    PMID: 33835757
  7. 7

    Management of late onset urea cycle disorders-a remaining challenge for the intensivist?

    Redant S, Empain A, Mugisha A, et al.

    Annals of intensive care 2021; (11(1)):2 doi:10.1186/s13613-020-00797-y.

    PMID: 33409766
  8. 8

    Sodium phenylbutyrate improved the clinical state in an adult patient with arginase 1 deficiency.

    Matsufuji M, Takeshita E, Nakashima M, et al.

    Brain & development 2020; (42(2)):231-235 doi:10.1016/j.braindev.2019.09.002.

    PMID: 31604595
  9. 9

    Profile of sodium phenylbutyrate granules for the treatment of urea-cycle disorders: patient perspectives.

    Peña-Quintana L, Llarena M, Reyes-Suárez D, Aldámiz-Echevarria L

    Patient preference and adherence 2017; (11()):1489-1496 doi:10.2147/PPA.S136754.

    PMID: 28919721
  10. 10

    Urinary phenylacetylglutamine (U-PAGN) concentration as biomarker for adherence in patients with urea cycle disorders (UCD) treated with glycerol phenylbutyrate.

    Mokhtarani M, Diaz GA, Lichter-Konecki U, et al.

    Molecular genetics and metabolism reports 2015; (5()):12-14 doi:10.1016/j.ymgmr.2015.09.003.

    PMID: 28649536
  11. 11

    Impact of long-term nitrogen scavenger therapy on clinical outcome in individuals with urea cycle disorders.

    Posset R, Epp F, Garbade SF, et al.

    Scientific reports 2026; doi:10.1038/s41598-026-42150-6.

    PMID: 41851188
  12. 12

    Outcome of Liver Transplantation for Neonatal-onset Citrullinemia Type I.

    Liu Y, Luo Y, Xia L, et al.

    Transplantation 2021; (105(3)):569-576 doi:10.1097/TP.0000000000003261.

    PMID: 33617202
  13. 13

    [Citrullinemia type I with recurrent liver failure in a child].

    Bindi V, Eiroa H

    Archivos argentinos de pediatria 2017; (115(1)):e39-e42 doi:10.5546/aap.2017.e39.

    PMID: 28097854
  14. 14

    Proposed Plasma Ammonia Reference Intervals in a Reference Group of Hospitalized Term and Preterm Neonates.

    Madigan T, Block DR, Carey WA, et al.

    The journal of applied laboratory medicine 2020; (5(2)):363-369 doi:10.1093/jalm/jfz001.

    PMID: 32445380

This page explains standard treatments for Citrullinemia type I for educational purposes only. Always consult your metabolic specialist or pediatrician before adjusting your child's diet, medications, or treatment plan.

Get notified when new evidence is published on Citrullinemia type I.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.